{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:57:47Z","timestamp":1788951467869,"version":"build-2803163510"},"reference-count":144,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T00:00:00Z","timestamp":1407369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Despite the availability of an inactivated vaccine that has been licensed for &gt;50 years, the influenza virus continues to cause morbidity and mortality worldwide. Constant evolution of circulating influenza virus strains and the emergence of new strains diminishes the effectiveness of annual vaccines that rely on a match with circulating influenza strains. Thus, there is a continued need for new, efficacious vaccines conferring cross-clade protection to avoid the need for biannual reformulation of seasonal influenza vaccines. Recombinant virus-vectored vaccines are an appealing alternative to classical inactivated vaccines because virus vectors enable native expression of influenza antigens, even from virulent influenza viruses, while expressed in the context of the vector that can improve immunogenicity. In addition, a vectored vaccine often enables delivery of the vaccine to sites of inductive immunity such as the respiratory tract enabling protection from influenza virus infection. Moreover, the ability to readily manipulate virus vectors to produce novel influenza vaccines may provide the quickest path toward a universal  vaccine protecting against all influenza viruses. This review will discuss experimental  virus-vectored vaccines for use in humans, comparing them to licensed vaccines and the hurdles faced for licensure of these next-generation influenza virus vaccines.<\/jats:p>","DOI":"10.3390\/v6083055","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T10:23:22Z","timestamp":1407407002000},"page":"3055-3079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Virus-Vectored Influenza Virus Vaccines"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-9956","authenticated-orcid":false,"given":"Ralph","family":"Tripp","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia, 111 Carlton St., Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tompkins","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia, 111 Carlton St., Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Deaths: Preliminary data for 2003","volume":"53","author":"Hoyert","year":"2005","journal-title":"Natl. Vital. Stat. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1086\/430424","article-title":"A national survey of severe influenza-associated complications among children and adults, 2003\u20132004","volume":"40","author":"Podewils","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","first-page":"1","article-title":"Prevention and control of influenza with vaccines: Recommendations of the advisory committee on immunization practices (acip), 2010","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm. Rep."},{"key":"ref_4","unstructured":"Centers for Disease Control and Prevention (CDC) (2013). Prevention and control of seasonal influenza with vaccines. Recommendations of the advisory committee on immunization practices\u2014United States, 2013\u20132014. MMWR Recomm. Rep., 62, 1\u201343."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00148581-200406040-00001","article-title":"Role of influenza vaccine for healthy children in the us","volume":"6","author":"Block","year":"2004","journal-title":"Paediatr. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00001432-200404000-00010","article-title":"Pneumonia in the elderly","volume":"17","author":"Loeb","year":"2004","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0733-8627(03)00018-X","article-title":"Influenza","volume":"21","author":"Olshaker","year":"2003","journal-title":"Emerg. Med. Clin. North Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.vaccine.2005.04.019","article-title":"The unmet need in the elderly: Designing new influenza vaccines for older adults","volume":"23","author":"McElhaney","year":"2005","journal-title":"Vaccine"},{"key":"ref_9","first-page":"43","article-title":"Seasonal influenza vaccines","volume":"333","author":"Fiore","year":"2009","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.292.11.1333","article-title":"Influenza-associated hospitalizations in the united states","volume":"292","author":"Thompson","year":"2004","journal-title":"JAMA"},{"key":"ref_11","first-page":"119","article-title":"Emergence and transmission of influenza a viruses resistant to amantadine and rimantadine","volume":"176","author":"Hayden","year":"1992","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_12","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014Recommendations of the advisory committee on immunization practices (acip)","volume":"60","author":"Fiore","year":"2011","journal-title":"MMWR Recomm. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/fvl.12.122","article-title":"Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses","volume":"8","author":"Mooney","year":"2013","journal-title":"Future Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/hv.8.1.18214","article-title":"Correlates of vaccine protection from influenza and its complications","volume":"8","author":"McCullers","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase","volume":"207","author":"Couch","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.vaccine.2012.10.065","article-title":"Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines","volume":"31","author":"Couch","year":"2012","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.vaccine.2009.10.066","article-title":"A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses","volume":"28","author":"Hassantoufighi","year":"2010","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM197206222862502","article-title":"Association of serum anti-neuraminidase antibody with resistance to influenza in man","volume":"286","author":"Murphy","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/129.4.411","article-title":"Induction of partial immunity to influenza by a neuraminidase-specific vaccine","volume":"129","author":"Couch","year":"1974","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1128\/JVI.01203-13","article-title":"Molecular basis for broad neuraminidase immunity: Conserved epitopes in seasonal and pandemic h1n1 as well as h5n1 influenza viruses","volume":"87","author":"Wan","year":"2013","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/jvi.2.8.778-786.1968","article-title":"Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice","volume":"2","author":"Schulman","year":"1968","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.vaccine.2014.01.078","article-title":"Stability of neuraminidase in inactivated influenza vaccines","volume":"32","author":"Sultana","year":"2014","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/S0264-410X(01)00143-8","article-title":"Live attenuated influenza virus vaccines: New options for the prevention of influenza","volume":"19","author":"Nichol","year":"2001","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.virusres.2004.02.031","article-title":"Current status of live attenuated influenza virus vaccine in the us","volume":"103","author":"Belshe","year":"2004","journal-title":"Virus Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3947\/ic.2013.45.4.375","article-title":"Influenza vaccines: Unmet needs and recent developments","volume":"45","author":"Noh","year":"2013","journal-title":"Infect. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/cc8891","article-title":"Bench-to-bedside review: Vaccine protection strategies during pandemic flu outbreaks","volume":"14","author":"Chua","year":"2010","journal-title":"Crit. Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e21937","DOI":"10.1371\/journal.pone.0021937","article-title":"Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against ph1n1 challenge in mice","volume":"6","author":"Soboleski","year":"2011","journal-title":"PLoS One"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1586\/erv.10.123","article-title":"Cross-protective immunity to influenza a viruses","volume":"9","author":"Epstein","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","article-title":"Toward a universal influenza virus vaccine: Prospects and challenges","volume":"64","author":"Pica","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7774\/cevr.2014.3.1.12","article-title":"New vaccines against influenza virus","volume":"3","author":"Lee","year":"2014","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.3390\/v4112711","article-title":"Advances and future challenges in recombinant adenoviral vectored h5n1 influenza vaccines","volume":"4","author":"Zhang","year":"2012","journal-title":"Viruses"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1590\/S0100-879X2005000400004","article-title":"Recombinant viruses as vaccines against viral diseases","volume":"38","author":"Souza","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_35","first-page":"18","article-title":"Vaccine delivery methods using viral vectors","volume":"4","author":"Ljungberg","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/milmed\/160.6.300","article-title":"Adenovirus vaccines in the United States Military","volume":"160","author":"Gaydos","year":"1995","journal-title":"Mil. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Levine, M., Kaper, J., Rappuoli, R., Liu, M., and Good, M. (2004). New Generation Vaccines, Marcel Dekker. [3rd ed.].","DOI":"10.1201\/9781439834404"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0264-410X(95)00032-V","article-title":"Adenovirus vectors as recombinant viral vaccines","volume":"13","author":"Imler","year":"1995","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1038\/sj.gt.3302616","article-title":"Purification of adenovirus and adeno-associated virus: Comparison of novel membrane-based technology to conventional techniques","volume":"12","author":"Duffy","year":"2005","journal-title":"Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00705-002-0870-y","article-title":"Recombinant adenovirus encoding the ha gene from swine h3n2 influenza virus partially protects mice from challenge with heterologous virus: A\/hk\/1\/68 (h3n2)","volume":"147","author":"Tang","year":"2002","journal-title":"Arch. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Shi","year":"2005","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts review of adenovirus vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/infdis\/jiq119","article-title":"The step study provides a hint that vaccine induction of the right cd8+ t cell responses can facilitate immune control of hiv","volume":"203","author":"Altfeld","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity hiv-1 vaccine (the step study): A double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"Hiv-1 vaccine-induced immunity in the test-of-concept step study: A case\u2014cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of hiv acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus hiv vaccine (step study)","volume":"206","author":"Duerr","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e62496","DOI":"10.1371\/journal.pone.0062496","article-title":"Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness","volume":"8","author":"Vemula","year":"2013","journal-title":"PLoS One"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3201\/eid1303.061125","article-title":"Matrix protein 2 vaccination and protection against influenza viruses, including subtype h5n1","volume":"13","author":"Tompkins","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1016\/j.vaccine.2009.08.053","article-title":"Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent h1n1 and h5n1 influenza a viruses","volume":"27","author":"Price","year":"2009","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1016\/j.vaccine.2005.04.047","article-title":"Protection against multiple influenza a subtypes by vaccination with highly conserved nucleoprotein","volume":"23","author":"Epstein","year":"2005","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1016\/j.vaccine.2004.02.040","article-title":"Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of h3n2 swine influenza virus","volume":"22","author":"Wesley","year":"2004","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e9812","DOI":"10.1371\/journal.pone.0009812","article-title":"Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against h5n1 influenza in mouse and ferret","volume":"5","author":"Rao","year":"2010","journal-title":"PLoS One"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","article-title":"Development of nonhuman adenoviruses as vaccine vectors","volume":"24","author":"Bangari","year":"2006","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e15301","DOI":"10.1371\/journal.pone.0015301","article-title":"A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an h5n1 virus disease model","volume":"5","author":"Patel","year":"2010","journal-title":"PLoS One"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e73313","DOI":"10.1371\/journal.pone.0073313","article-title":"Low seroprevalent species d adenovirus vectors as influenza vaccines","volume":"8","author":"Weaver","year":"2013","journal-title":"PLoS One"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1089\/104454902762053855","article-title":"Adenovirus and adeno-associated virus vectors","volume":"21","author":"Lai","year":"2002","journal-title":"DNA Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.1128\/jvi.71.10.7960-7962.1997","article-title":"Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins b and d","volume":"71","author":"Manning","year":"1997","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Nieto, K., and Salvetti, A. (2014). Aav vectors vaccines against infectious diseases. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00005"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/104303401750214276","article-title":"A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus","volume":"12","author":"Xin","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1128\/JVI.01441-09","article-title":"A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque","volume":"83","author":"Lin","year":"2009","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"187ra172","DOI":"10.1126\/scitranslmed.3006299","article-title":"Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza","volume":"5","author":"Limberis","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nbt.2618","article-title":"Broad protection against influenza infection by vectored immunoprophylaxis in mice","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-386509-0.00012-0","article-title":"Chapter twelve\u2014Adeno-associated virus vectorology, manufacturing, and clinical applications","volume":"Volume 507","author":"Friedmann","year":"2012","journal-title":"Methods in Enzymology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/rmv.360","article-title":"Alphavirus vectors and vaccination","volume":"12","author":"Rayner","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated venezuelan equine encephalitis virus: Expression of heterologous genesin vitroand immunization against heterologous pathogensin vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1128\/JVI.72.8.6907-6910.1998","article-title":"Recombinant sindbis viruses expressing a cytotoxic t-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice","volume":"72","author":"Tsuji","year":"1998","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/viro.2000.0635","article-title":"Influenza virus (a\/hk\/156\/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with hong kong-origin h5n1 viruses","volume":"278","author":"Dybing","year":"2000","journal-title":"Virology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0264-410X(98)00224-2","article-title":"Immunization with recombinant semliki forest virus induces protection against influenza challenge in mice","volume":"17","author":"Berglund","year":"1999","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JVI.01805-10","article-title":"Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus","volume":"85","author":"Sheahan","year":"2011","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/viro.1996.8381","article-title":"Mucosal immunity induced by parenteral immunization with a live attenuated venezuelan equine encephalitis virus vaccine candidate","volume":"228","author":"Charles","year":"1997","journal-title":"Virology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1073\/pnas.0600287103","article-title":"Mucosal and systemic adjuvant activity of alphavirus replicon particles","volume":"103","author":"Thompson","year":"2006","journal-title":"Proc. Nat.l. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in cmv seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0167-7799(01)01911-4","article-title":"Recombinant baculoviruses as mammalian cell gene-delivery vectors","volume":"20","author":"Kost","year":"2002","journal-title":"Trends Biotechnol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4049\/jimmunol.171.3.1133","article-title":"Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice","volume":"171","author":"Abe","year":"2003","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.molimm.2009.04.017","article-title":"A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with h5n1 avian influenza virus in mice and chickens","volume":"46","author":"Wu","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.antiviral.2011.10.001","article-title":"Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent h5n1 influenza vaccine","volume":"92","author":"Wu","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.virol.2008.08.002","article-title":"Protective immunity against influenza h5n1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed ha and recombinant ctb as an adjuvant","volume":"380","author":"Prabakaran","year":"2008","journal-title":"Virology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.antiviral.2010.02.315","article-title":"Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against h5n1 infection in mice","volume":"86","author":"Prabakaran","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.vaccine.2013.01.003","article-title":"Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza h5n1 challenge","volume":"31","author":"Prabakaran","year":"2013","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ps\/82.6.899","article-title":"Recombinant newcastle disease virus as a vaccine vector","volume":"82","author":"Huang","year":"2003","journal-title":"Poult. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of newcastle disease virus from cloned cdna: Evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1099\/0022-1317-80-11-2987","article-title":"Generation of recombinant lentogenic newcastle disease virus from cdna","volume":"80","author":"Mundt","year":"1999","journal-title":"J. Gen. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1128\/JVI.75.23.11868-11873.2001","article-title":"Recombinant newcastle disease virus as a vaccine vector","volume":"75","author":"Nakaya","year":"2001","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8197","DOI":"10.1073\/pnas.0602461103","article-title":"Newcastle disease virus expressing h5 hemagglutinin gene protects chickens against newcastle disease and avian influenza","volume":"103","author":"Veits","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1073\/pnas.0602566103","article-title":"Engineered viral vaccine constructs with dual specificity: Avian influenza and newcastle disease","volume":"103","author":"Park","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1637\/0005-2086-47.s3.1047","article-title":"Recombinant paramyxovirus type 1-avian influenza-h7 virus as a vaccine for protection of chickens against influenza and newcastle disease","volume":"47","author":"Swayne","year":"2003","journal-title":"Avian Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JVI.01514-06","article-title":"Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous h5n1 avian influenza viruses","volume":"81","author":"Ge","year":"2007","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e6509","DOI":"10.1371\/journal.pone.0006509","article-title":"Immunization of chickens with newcastle disease virus expressing h5 hemagglutinin protects against highly pathogenic h5n1 avian influenza viruses","volume":"4","author":"Nayak","year":"2009","journal-title":"PLoS One"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1637\/9652-011111-Reg.1","article-title":"Coexpression of avian influenza virus h5 and n1 by recombinant newcastle disease virus and the impact on immune response in chickens","volume":"55","author":"Ramp","year":"2011","journal-title":"Avian Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e44447","DOI":"10.1371\/journal.pone.0044447","article-title":"Protective efficacy of newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic h5n1 influenza in chickens and mice","volume":"7","author":"Cornelissen","year":"2012","journal-title":"PLoS One"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1128\/JVI.01946-09","article-title":"Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of h5n1 highly pathogenic avian influenza virus protect against virus challenge in monkeys","volume":"84","author":"DiNapoli","year":"2010","journal-title":"J. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1128\/JVI.00713-07","article-title":"Immunization of primates with a newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus","volume":"81","author":"DiNapoli","year":"2007","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e31177","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza h5 hemagglutinin","volume":"7","author":"Alexander","year":"2012","journal-title":"PLoS One"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.virol.2006.12.005","article-title":"Recombinant parainfluenza virus 5 (piv5) expressing the influenza a virus hemagglutinin provides immunity in mice to influenza a virus challenge","volume":"362","author":"Tompkins","year":"2007","journal-title":"Virology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e50144","DOI":"10.1371\/journal.pone.0050144","article-title":"Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/JVI.02321-12","article-title":"Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza a virus h5n1 protected mice against lethal highly pathogenic avian influenza virus h5n1 challenge","volume":"87","author":"Li","year":"2013","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/JVI.02330-12","article-title":"Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against h5n1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of balb\/c mice","volume":"87","author":"Mooney","year":"2013","journal-title":"J. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1128\/JVI.00120-13","article-title":"Single-dose vaccination of a recombinant parainfluenza virus 5 expressing np from h5n1 virus provides broad immunity against influenza a viruses","volume":"87","author":"Li","year":"2013","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2013.05.091","article-title":"Utilizing poxviral vectored vaccines for antibody induction\u2014progress and prospects","volume":"31","author":"Draper","year":"2013","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1073\/pnas.79.16.4927","article-title":"Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus","volume":"79","author":"Panicali","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.79.23.7415","article-title":"Vaccinia virus: A selectable eukaryotic cloning and expression vector","volume":"79","author":"Mackett","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1073\/pnas.80.23.7155","article-title":"Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters","volume":"80","author":"Smith","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0042-6822(87)90004-3","article-title":"Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses","volume":"160","author":"Smith","year":"1987","journal-title":"Virology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1073\/pnas.93.21.11349","article-title":"Applications of pox virus vectors to vaccination: An update","volume":"93","author":"Paoletti","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes mva","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"Nyvac: A highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Micro"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated mva strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2013.03.016","article-title":"Protective efficacy of modified vaccinia virus ankara in preclinical studies","volume":"31","author":"Volz","year":"2013","journal-title":"Vaccine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1128\/JVI.02216-07","article-title":"Differential CD4+ versus cd8+ t-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates","volume":"82","author":"Mooij","year":"2008","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc. Nat.l. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e1000480","DOI":"10.1371\/journal.ppat.1000480","article-title":"Innate immune sensing of modified vaccinia virus ankara (mva) is mediated by tlr2-tlr6, mda-5 and the nalp3 inflammasome","volume":"5","author":"Delaloye","year":"2009","journal-title":"PLoS Pathog."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a t-cell-based influenza vaccine, mva-np+m1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ t-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, mva-np+m1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e48322","DOI":"10.1371\/journal.pone.0048322","article-title":"A t cell-inducing influenza vaccine for the elderly: Safety and immunogenicity of mva-np+m1 in adults aged over 50 years","volume":"7","author":"Antrobus","year":"2012","journal-title":"PLoS One"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02108-05","article-title":"Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (mva and nyvac) and role of the c7l gene","volume":"80","author":"Gherardi","year":"2006","journal-title":"J. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.0705191105","article-title":"Aerosol immunization with nyvac and mva vectored vaccines is safe, simple, and immunogenic","volume":"105","author":"Corbett","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.vaccine.2009.02.006","article-title":"Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic h5n1 avian influenza virus in pigs","volume":"27","author":"Kyriakis","year":"2009","journal-title":"Vaccine"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1099\/vir.0.2008\/004440-0","article-title":"Vaccinia virus strain nyvac induces substantially lower and qualitatively different human antibody responses compared with strains lister and dryvax","volume":"89","author":"Midgley","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1373.023","article-title":"Development and use of fowlpox vectored vaccines for avian influenza","volume":"1081","author":"Bublot","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1051\/vetres:2004019","article-title":"Equine viral vaccines: The past, present and future","volume":"35","author":"Minke","year":"2004","journal-title":"Vet. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/CMR.00005-07","article-title":"Current status of veterinary vaccines","volume":"20","author":"Meeusen","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_127","first-page":"21","article-title":"Edward jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proceedings"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J. Virol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.72.6.4704-4711.1998","article-title":"Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge","volume":"72","author":"Roberts","year":"1998","journal-title":"J. Virol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: Re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1128\/jvi.71.8.5982-5989.1997","article-title":"High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses","volume":"71","author":"Kretzschmar","year":"1997","journal-title":"J. Virol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1128\/JVI.02637-09","article-title":"Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge","volume":"84","author":"Schwartz","year":"2010","journal-title":"J. Virol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1128\/JVI.02491-10","article-title":"Vesicular stomatitis virus-based h5n1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques","volume":"85","author":"Schwartz","year":"2011","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virol.2007.04.021","article-title":"Vesicular stomatitis virus vectors expressing avian influenza h5 ha induce cross-neutralizing antibodies and long-term protection","volume":"366","author":"Schwartz","year":"2007","journal-title":"Virology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-3-540-92165-3_13","article-title":"Recombinant vectors as influenza vaccines","volume":"Volume 333","author":"Compans","year":"2009","journal-title":"Vaccines for Pandemic Influenza"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.66.1.15","article-title":"Influence of host factors on neuroinvasiveness of vesicular stomatitis virus: I. Effect of age on the invasion of the brain by virus instilled in the nose","volume":"66","author":"Sabin","year":"1937","journal-title":"J. Exp. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","article-title":"Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates","volume":"360","author":"Johnson","year":"2007","journal-title":"Virology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/311578a0","article-title":"Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic t cells","volume":"311","author":"Bennink","year":"1984","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1073\/pnas.82.6.1785","article-title":"Influenza a virus nucleoprotein is a major target antigen for cross-reactive anti-influenza a virus cytotoxic t lymphocytes","volume":"82","author":"Yewdell","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1099\/0022-1317-67-4-719","article-title":"Recognition of influenza a virus nucleoprotein by human cytotoxic t lymphocytes","volume":"67","author":"McMichael","year":"1986","journal-title":"J. Gen. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1128\/jvi.57.3.786-791.1986","article-title":"Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic t lymphocytes","volume":"57","author":"Bennink","year":"1986","journal-title":"J. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e88340","DOI":"10.1371\/journal.pone.0088340","article-title":"Mva vectors expressing conserved influenza proteins protect mice against lethal challenge with h5n1, h9n2 and h7n1 viruses","volume":"9","author":"Hessel","year":"2014","journal-title":"PLoS One"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.antiviral.2013.03.021","article-title":"Broadly neutralizing antibodies against influenza viruses","volume":"98","author":"Laursen","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., Garc\u00eda-Sastre, A., and Palese, P. (2010). Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio, 1.","DOI":"10.1128\/mBio.00018-10"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/6\/8\/3055\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:14:30Z","timestamp":1760217270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/6\/8\/3055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":144,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8]]}},"alternative-id":["v6083055"],"URL":"https:\/\/doi.org\/10.3390\/v6083055","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]}}}